People: POZEN Inc. (POZN.O)

POZN.O on Consolidated Issue listed on NASDAQ Global Market

5.74USD
9 Feb 2010
Price Change (% chg)

$0.16 (+2.87%)
Prev Close
$5.74
Open
--
Day's High
$5.79
Day's Low
$5.63
Volume
41,038
Avg. Vol
78,539
52-wk High
$8.42
52-wk Low
$4.50

view people for:

Summary

Name Age Since Current Position
Plachetka, John 55 2001 Chairman of the Board, President, Chief Executive Officer
Hodges, William 54 2004 Chief Financial Officer, Senior Vice President - Finance and Administration
Cermak, Elizabeth 2009 Executive Vice President, Chief Commercial Officer
Thomas, Gilda 54 2007 Senior Vice President, General Counsel
Orlemans, Everardus 52 2009 Senior Vice President - Product Development
Barnhardt, John 59 2004 Vice President - Finance and Administration
Fort, John 54 2007 Chief Medical Officer
Lee, Kenneth 61 2005 Lead Independent Director
Rejeange, Jacques 69 2007 Director
Kirsch, Arthur 57 2004 Director
Mauzey, James 60 2006 Director
Larson, Angela 2009 Director
» Insider Trading

Biographies

Name Description
Plachetka, John Mr. John R. Plachetka, Pharm.D., has been Chairman of the Board of POZEN Inc. since January 2001, co-founder of POZEN and President and Chief Executive Officer of POZEN since 1996; Vice President of Development at Texas Biotechnology Corporation from 1993 to 1995.
Hodges, William Mr. William L. Hodges is Senior Vice President of Finance and Administration and Chief Financial Officer of POZEN Inc. since August 2004 . Mr. Hodges began his career in the pharmaceutical industry with Burroughs Wellcome Co. in 1985. In 1991, he moved to London and worked in Group Finance for the Wellcome Foundation, Ltd. within Group Finance. Mr. Hodges worked on mergers and acquisitions and was Regional Controller for Northern Europe and Japan. In 1993, he returned to Burroughs Wellcome in North Carolina as Director of Procurement. Mr. Hodges was Vice President, Corporate Planning and Business Support at GlaxoWellcome before being appointed acting Senior Vice President and CFO for the fifteen months up to the merger between GlaxoWellcome plc and SmithKline Beecham plc which was completed in December of 2000. Prior to joining POZEN, Mr. Hodges was Senior Vice President and CFO of Pergo, Inc. located in Raleigh, North Carolina. Mr. Hodges received his B.S. from the University of North Carolina at Chapel Hill and is a Certified Public Accountant.
Cermak, Elizabeth Ms. Elizabeth A. Cermak is Executive Vice President, Chief Commercial Officer of POZEN Inc. Ms. Cermak was employed for twenty-five years at Johnson & Johnson, where she held positions of increasing responsibility at Ortho-McNeil Pharmaceuticals, McNeil Consumer and Specialty Pharmaceuticals and other Johnson and Johnson subsidiaries. She most recently held the position of World-Wide Vice President Personal Products Franchise, Johnson & Johnson Healthcare Products. Her experience spans both prescription and OTC businesses across many therapeutic areas. She specialized in sales and marketing and has managed large and small business units both domestically and outside the US. In addition, she has expertise in business development and finance. Ms. Cermak received a Bachelor of Arts from Franklin and Marshall College and an Master of Business Administration from Drexel University.
Thomas, Gilda Ms. Gilda M. Thomas is Senior Vice President and General Counsel of POZEN Inc. since January 2007. Prior to joining POZEN, Ms. Thomas was Vice President, General Counsel and company secretary at EMD Pharmaceuticals, Inc., an affiliate of Merck KGaA, Darmstadt, Germany from July 2001 to December 2006. Prior to joining EMD, she spent 14 years at Burroughs Wellcome Co., which merged into Glaxo Welcome, Inc. At Glaxo Wellcome Ms. Thomas was Associate General Counsel responsible for the 13 member corporate section of the legal department. Ms. Thomas received her J.D. from Harvard Law School, a M.S. from Simmons College and a B.A. from Wellesley College.
Orlemans, Everardus Mr. Everardus Orlemans , Ph.D. is Senior Vice President, Product Development of POZEN Inc. since January 2009. He joined POZEN in November 2005 as Vice President, Clinical Research and was promoted to Senior Vice President, Product Development in January 2009. Dr. Orlemans began his professional career with Organon NV, a pharmaceutical company based in the Netherlands, before transferring to its U.S. subsidiary, Organon Pharmaceuticals USA, Inc., where his most recent position was Executive Director of the Clinical Development Unit. Dr. Orlemans was an employee of Organon NV and/or its U.S. Subsidiary from October 1988 to March 2005. He received a M.S. in Chemistry from Catholic University of Nijmegen in the Netherlands and his Ph.D. degree from the University of Twente, also located in the Netherlands.
Barnhardt, John Mr. John E. Barnhardt serves as Vice President - Finance and Administration of POZEN Inc. He joined POZEN in 1997 as Vice President, Finance and Administration and Principal Accounting Officer. Prior to joining POZEN, Mr. Barnhardt held finance and accounting positions with publicly traded companies beginning in 1988. These positions included Chief Financial Officer of Medco Research, Inc., engaged in the research and development of pharmaceutical products primarily for the diagnosis and treatment of cardiovascular disease, and Principal Accounting Officer of Microwave Laboratories, Inc., a defense contractor developing and manufacturing traveling wave tubes for electronic countermeasure systems. Mr. Barnhardt received his B.S. in Zoology from North Carolina State University, and while employed at Ernst & Ernst (now Ernst & Young LLP), became a Certified Public Accountant.
Fort, John Dr. John G. Fort, M.D. is Chief Medical Officer of POZEN since July 2007. Prior to joining POZEN, Dr. Fort was Vice President, Medical Affairs at Adolor Corporation and held positions with Pfizer Inc., including Vice President, Medical Affairs, and was Vice President, Arthritis and Pain at G.D. Searle & Co., Monsanto Corporation from September 1994 to December 2003. Prior to joining the pharmaceutical industry, he was an Associate Professor of Medicine at Thomas Jefferson University, Division of Rheumatology. Dr. Fort received his M.D. from the University of Valencia Faculty of Medicine and is board certified in internal medicine with a subspecialty certification in rheumatology.
Lee, Kenneth Mr. Kenneth B. Lee, Jr. is Lead Independent Director of POZEN Inc. since 2005. He has been Independent consultant since June 2002 and general partner of Hatteras Venture Partners (formerly Hatteras BioCapital. LLC and BioVista Capital, LLC), the general partner of Hatteras BioCapital Fund, L.P., a venture capital fund focusing on life sciences companies, since 2003; President of A.M. Pappas & Associates, a venture capital firm, between January 2002 and June 2002; Partner of Ernst & Young LLP from 1982 through 2000; Partner of Ernst & Young Corporate Finance LLC from 2000 to 2001; Managing Director of Ernst & Young’s Health Sciences Corporate Finance Group from 2000 to 2001. Serves on the boards of the following public companies: CV Therapeutics Inc., for which he serves as chair of the audit committee and member of the compensation committee, OSI Pharmaceuticals, for which he serves as a member of the audit committee and oncology committee, and Inspire Pharmaceuticals Inc., for which he serves as chairman of the board of directors, chair of the audit committee and member of the compensation committee.
Rejeange, Jacques Mr. Jacques F. Rejeange serves as Director of POZEN Inc. He is Retired since 2005. He has been President of Florham Consulting S.A., a healthcare consulting company based in Areuse, Switzerland, from 1995 to 2005. Served as member of board of directors of POZEN from 1997 to 2004 (Chairman from 1999 to 2000); retired from the Board in 2004. Formerly served on the boards of Amersham PLC (UK), Swiss Red Cross Foundation (CH) and NMY AG (CH). Currently serves on the board of Swisslog AG.
Kirsch, Arthur Mr. Arthur S. Kirsch serves as Director of POZEN Inc. He is Senior Advisor, GCA Savvian, LLC (formerly Perseus Group, LLC), an investment bank, since June 2005; founding member and Managing Director of Vector Securities, LLC, an investment and merchant banking firm, from 2001 to May 2005; Managing Director and Head of Healthcare Research and Capital Markets of Prudential Vector Healthcare Group, a unit of Prudential Securities, Inc., a full-service brokerage firm, from 1999 to 2001; Director, Equity Research of Vector Securities International, Inc., an investment banking firm, from 1995 to 1999.
Mauzey, James Mr. James J. Mauzey serves as Director of POZEN Inc. He is Retired since July 2004 and is President and Chief Executive Officer of Bertek Pharmaceuticals Inc., a pharmaceutical products company and division of Mylan Laboratories, from October 2000 through July 2004; Chief Executive Officer of Innovex Worldwide, a division of Quintiles Transnational Corporation from 1999 to 2000. From 1997 to 2003, served as a director of OraPharma, Inc., a public specialty pharmaceutical company acquired by Johnson & Johnson in 2003.
Larson, Angela Angela Maria Larson has been appointed to the board of directors of POZEN Inc. on June 3, 2009. Ms. Larson is President, Larson Pharm Consult, LLC a pharmaceutical industry focused corporate development business strategy consulting firm, and President, Fierce Fun Toys, LLC, a toy manufacturer and retailer. Previously, Ms. Larson was an equity research analyst focused on the Specialty Pharmaceutical sector for a number of large and small financial firms, including SmithBarney/CitiGroup, Susquehanna International Group, PaineWebber, and C.E. Unterberg Towbin. While at Unterberg Towbin, she became the Director of Research and a member of the company's operating committee which was responsible for firm strategy, budgeting, and forecasting.

Basic Compensation

Name Fiscal Year Total
Plachetka, John 2,244,440
Hodges, William 1,053,190
Cermak, Elizabeth --
Thomas, Gilda 601,995
Orlemans, Everardus --
Barnhardt, John 623,095
Fort, John --
Lee, Kenneth --
Rejeange, Jacques --
Kirsch, Arthur --
Mauzey, James --
Larson, Angela --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Plachetka, John 980,322 2,719,130
Hodges, William 146,645 429,367
Cermak, Elizabeth 0 0
Thomas, Gilda 0 0
Orlemans, Everardus 0 0
Barnhardt, John 226,853 1,140,353
Fort, John 0 0
Lee, Kenneth 0 0
Rejeange, Jacques 0 0
Kirsch, Arthur 0 0
Mauzey, James 0 0
Larson, Angela 0 0

Insider Trading

Name Shares Traded Price
PLACHETKA JOHN R 12,500 $0.00
PLACHETKA JOHN R 500 $6.73
PLACHETKA JOHN R 328 $6.95
PLACHETKA JOHN R 250 $6.85
PLACHETKA JOHN R 1,440 $6.70
PLACHETKA JOHN R 800 $6.91
PLACHETKA JOHN R 100 $6.83
PLACHETKA JOHN R 800 $6.75
PLACHETKA JOHN R 1,000 $6.88
PLACHETKA JOHN R 4,972 $6.80
PLACHETKA JOHN R 600 $6.72
PLACHETKA JOHN R 200 $6.94
PLACHETKA JOHN R 100 $6.74
PLACHETKA JOHN R 300 $6.84
PLACHETKA JOHN R 700 $6.78
PLACHETKA JOHN R 300 $6.90
PLACHETKA JOHN R 110 $6.81
PLACHETKA JOHN R 400 $6.83
PLACHETKA JOHN R 700 $6.79
PLACHETKA JOHN R 2,473 $6.82
PLACHETKA JOHN R 500 $6.76
PLACHETKA JOHN R 1,900 $6.80
PLACHETKA JOHN R 1,445 $6.77
PLACHETKA JOHN R 4,132 $6.78
PLACHETKA JOHN R 950 $6.81
» Full list on Insider Trading
view people for: